Kestrel Health Receives CE Mark for AI-Assisted Retinal Screening Device
The handheld device enables primary-care clinics to screen for diabetic retinopathy in under four minutes without a specialist on site.
DUBLIN β Kestrel Health has received CE marking for KestrelView, a handheld retinal screening device that uses on-device artificial intelligence to flag signs of diabetic retinopathy in primary-care settings.
Screening where patients already are
KestrelView captures a retinal image and returns a referral recommendation in under four minutes. Clinics can screen patients during routine diabetes appointments rather than referring them to hospital eye departments, where waiting lists in several countries exceed six months.
"Most sight loss from diabetes is preventable if it is caught early," said Dr. Amara Bello, Chief Medical Officer. "Putting screening in the clinic patients already visit removes the biggest barrier to that."
Clinical evidence
In a multi-site study of 4,120 patients, the device achieved 94 percent sensitivity and 91 percent specificity against specialist grading. Full results have been submitted for peer review.
About Kestrel Health
Kestrel Health develops point-of-care diagnostic devices for chronic disease management and is headquartered in Dublin, Ireland.
